Breaking Update
New Israel-U.S. Partnership Aims to Restore Nerve Function in MS
An Israeli-U.S. partnership launches a novel therapy to repair neurological damage in MS, using AI to identify molecules that restore myelin and reverse.
Jerusalem, 8 January, 2026 (TPS-IL) โ Israeli computational chemistry company Evogene Ltd. has partnered with Boston-based Unravel Biosciences to develop a first-in-class therapy aimed at repairing neurological damage in demyelinating disorders such as multiple sclerosis.
The collaboration combines Evogeneโs AI-driven ChemPass platform for generative small-molecule design with Unravelโs patient-derived BioNAV system and Living Molecular Twins. Together, they aim to identify and optimize brain-penetrant molecules capable of restoring myelin and reversing neurological degenerationโan unmet need in current treatments that focus only on slowing disease progression. Clinical applications could extend to other complex neurodegenerative conditions.
